Stock since the trade -3.1% · S&P 500 -0.2% · to Oct 1Traded 53 days after results
20K → 20K shares held
Becton Dickinson's Chief Revenue Officer sold $14K of Becton Dickinson shares. Nobody planned it ahead of time.
BDX · NYSE · Health Care Equipment
Health Care Equipment company based in Franklin Lakes, New Jersey.
Last close, Oct 1, 2026
$178.07
Adjusted for splits and dividends
Last 12 months
-6.7%
S&P 500 +14.3% over the same dates
Market value
$48.5B
Last close × shares outstanding
Bets against the stock: 11.3M shares sold short (4.2% of shares outstanding), +6.0% vs the previous count, 7.2 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
5 sales
$1.27M sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$21.8B
+8.2% vs the year before
Net income, fiscal 2025
$1.68B
As reported in the annual filing
Shares outstanding
272M
As of Jun 30, 2026
In fiscal 2025 the company spent $1B buying back its own shares and $1.2B on dividends. Cash actually paid, from its cash-flow statement.
Stock since the trade -3.1% · S&P 500 -0.2% · to Oct 1Traded 53 days after results
20K → 20K shares held
Becton Dickinson's Chief Revenue Officer sold $14K of Becton Dickinson shares. Nobody planned it ahead of time.
Officer plans to sell ~$14K of Becton Dickinson
Planned, from payStock since the trade -6.4% · S&P 500 -0.3% · to Oct 1Traded 20 days after resultsStock 35% above its 52-week low and 9% below its high, after a 23% rise in the previous month
20K → 20K shares held−1% of their stake
Becton Dickinson's Chief Revenue Officer sold $31K of Becton Dickinson shares. Nobody planned it ahead of time.
Stock since the trade -2.1% · S&P 500 -1.8% · to Oct 1Traded 7 days after resultsStock up 19% in the previous month
114K → 110K shares held−4% of their stake
The boss of Becton Dickinson sold $768K of Becton Dickinson shares. Nobody planned it ahead of time.
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
2 notices filed with state agencies, covering 66 workers in total. Employers must warn the state ahead of a plant closing or mass layoff at a site.
Official WARN lists from California, Texas, New York, Florida, Illinois and Washington only; notices filed in other states are not shown. Matched on the employer name as filed, so a notice filed under an unrelated subsidiary name can be missing. Dates are the notice date (Washington: the date the state received it).
51 certified in FY2026 Q3, vs 89 a year earlier. 51 positions in total, median offered wage $118K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Vanguard Capital Management
Schedule 13G: passive · filed Apr 29, 2026 · 21.4M shares
STATE STREET CORPORATION
Schedule 13G: passive · filed Aug 7, 2026 · 15M shares
Vanguard Portfolio Management
Schedule 13G: passive · filed Apr 29, 2026 · 15.4M shares
First Eagle Investment Management, LLC
Schedule 13G: passive · filed Aug 6, 2026 · 14.1M shares
Anyone owning more than 5% must file within days. Structured filings exist since December 2024, so older stakes that were never amended may be missing.
Short sale volume: 51.0% of the volume reported to FINRA over the last 20 trading days was marked short, close to its 1-year average of 49.6%. FINRA daily files, to Oct 2, 2026.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock.
Last 12 months, adjusted daily closes
Adjusted close went from $190.94 on Oct 1, 2025 to $178.07 on Oct 1, 2026 (-6.7%). Disclosed trades in the last 12 months: 0 insider purchases, 22 insider sales (4 under pre-arranged plans), 1 Congress purchase, 2 Congress sales.
Top officer leaving
“Garrison, Executive Vice President and President of the Medical Essentials and BioPharma Systems segments of Becton, Dickinson and Company (“BD”), informed BD of his intention to retire.”
3 insiders sold ~$754K in the 60 days before
8-K on sec.govTop officer leaving
“Byrd, Executive Vice President and President of the Interventional segment of Becton, Dickinson and Company (“BD”), informed BD of his intention to retire.”
2 insiders sold ~$199K in the 60 days before
8-K on sec.govTop officer leaving
“DelOrefice informed Becton, Dickinson and Company (the “Company” or “BD”) of his intention to resign from his position as the Company’s Executive Vice President and Chief Financial Officer effective December 5, 2025 to pursue a new professional opportunity.”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
19 approvals or clearances and 80 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.